VYNE Therapeutics Inc./$VYNE
VYNE Therapeutics shares are trading lower after the company updated its VYN202 program following an FDA clinical hold on its Phase 1b trial.
6 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Ticker
$VYNE
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
13
ISIN
US92941V3087
Website
VYNE Metrics
BasicAdvanced
$29M
-
-$0.99
1.58
-
Price and volume
Market cap
$29M
Beta
1.58
52-week high
$2.60
52-week low
$0.85
Average daily volume
857K
Financial strength
Current ratio
4.468
Quick ratio
4.09
Total debt to equity
0.143
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-6,974.55%
Operating margin (TTM)
-7,513.06%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-38.36%
Return on equity (TTM)
-66.15%
Valuation
Price to revenue (TTM)
124.674
Price to book
0.64
Price to tangible book (TTM)
0.64
Price to free cash flow (TTM)
-2.008
Free cash flow yield (TTM)
-49.81%
Free cash flow per share (TTM)
-88.17%
Growth
Revenue change (TTM)
43.03%
Earnings per share change (TTM)
-31.89%
3-year revenue growth (CAGR)
-11.71%
10-year revenue growth (CAGR)
-18.10%
3-year earnings per share growth (CAGR)
-60.70%
10-year earnings per share growth (CAGR)
-33.72%
VYNE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for VYNE Therapeutics Inc. stock?
VYNE Therapeutics Inc. (VYNE) has a market cap of $29M as of July 03, 2025.
What is the P/E ratio for VYNE Therapeutics Inc. stock?
The price to earnings (P/E) ratio for VYNE Therapeutics Inc. (VYNE) stock is 0 as of July 03, 2025.
Does VYNE Therapeutics Inc. stock pay dividends?
No, VYNE Therapeutics Inc. (VYNE) stock does not pay dividends to its shareholders as of July 03, 2025.
When is the next VYNE Therapeutics Inc. dividend payment date?
VYNE Therapeutics Inc. (VYNE) stock does not pay dividends to its shareholders.
What is the beta indicator for VYNE Therapeutics Inc.?
VYNE Therapeutics Inc. (VYNE) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.